Erythema nodosum leprosum in Nepal: A retrospective study of clinical features and response to treatment with prednisolone or thalidomide

Leprosy Review

Volumn 79, Issue 3, 2008, Pages 254-269

  Feuth, M ^a   Brandsma, J Wim ^b,e   Faber, W R ^a   Bhattarai, B ^b   Feuth, T ^c   Anderson, A M ^b,d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Green Pastures Hospital and Rehabilitation Centre Nepal   (Nepal)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d International Nepal Fellowship   (Nepal)

^e All Africa Leprosy Tuberculosis Rehabilitation Research and Training Centre   (Ethiopia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; PREDNISOLONE; THALIDOMIDE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DELAYED DIAGNOSIS; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; ERYTHEMA NODOSUM LEPROSUM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; NEPAL; RECURRENT DISEASE; SCHOOL CHILD; SCORING SYSTEM; THERAPY DELAY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CHILD; ERYTHEMA NODOSUM; FEMALE; HUMANS; LEPROSTATIC AGENTS; LEPROSY, LEPROMATOUS; MALE; MIDDLE AGED; MYCOBACTERIUM LEPRAE; NEPAL; PREDNISOLONE; SEVERITY OF ILLNESS INDEX; THALIDOMIDE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 56449119591     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. World Health Organization. Global leprosy situation. Weekly Epidem Rec, 2005; 80: 289-296.
2. Pocaterra L, Jain S, Reddy R et al. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med, 2006; 74: 868-879.
3. Walker SL, Lockwood DNJ. Leprosy. Clin Dermat, 2007; 25: 165-172.
4. Van Brakel WH, Khawas IB, Lucas SB. Reactions in leprosy: an epidemiological study of 386 patients in West Nepal. Lepr Rev, 1994; 65: 190-203.
5. Ridley DS. Reactions in leprosy. Lepr Rev, 1969; 40: 77-81.
6. Yawalkar SJ. Leprosy for medical practitioners and paramedical workers 7th edn, 2002, Ciba Geigy, Basle.
7. Bjune G. Reactions in leprosy. Lepr Rev, 1983; 61: S61-S67.
8. Saunderson P, Gebre S, Desta K et al. The pattern of leprosy-related neuropathy in the AMFES patients: definitions, risk factors and outcome. Lepr Rev, 2000; 71: 285-308.
9. Saunderson P, Gebre S, Byass P. ENL reactions in the multibacillary cases of the AMFES cohort in central Ethiopia: incidence and risk factors. Lepr Rev, 2000; 71: 318-324.
10. Saunderson P. Epidemiology of reactions and nerve damage. Lepr Rev, 2000; 71: S106-S110.
11. Manandhar R, LeMaster JW, Roche PW. Risk factors for erythema nodosum leprosum. Int J Lepr, 1999; 67: 270-278.
12. Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from North India. Int J Lepr, 2004; 72: 125-133.
13. Becx-Bleumink M. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy: experience in the leprosy control program of the all Africa Leprosy and Rehabilitation Training Centre (ALERT) in Ethiopia. Int J Lepr, 1992; 60: 173-184.
14. Brakel WH, Nicholls PG, Das L et al. The INFIR cohort study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in North India. Lepr Rev, 2005; 76: 14-34.
15. Sheskin J, Convit J. Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr, 1969; 37: 135-146.
16. Pearson JMH, Vedagir M. Treatment of moderately severe erythema nodosum leprosum with thalidomide - a double blind controlled trial. Lepr Rev, 1969; 40: 111-116.
17. Waters MFR. An internally controlled double blind trial of thalidomide in severe erythema nodosum leprosum. Lepr Rev, 1971; 42: 26-42.
18. Iyer CGS, Languillon J, Ramanujam K et al. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. Bull World Health Org, 1971; 45: 719-732.
19. Sales AM, Matos de HJ, Nery JAC et al. Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type-2 reaction in leprosy. Braz J Med Biol Res, 2007; 40: 243-248.
20. Lockwood DNJ. The management of erythema leprosum nodosum: current and future options. Lepr Rev, 1996; 67: 253-259.
21. Pannikar VC. The return of thalidomide: new uses and renewed concerns. Lepr Rev, 2003; 74: 286-288.
22. Teo SK, Resztak KE, Scheffer MA et al. Thalidomide in the treatment of leprosy. Microbes Inf, 2002; 4: 1193-1202.
23. Tadesse A, Shannon EJ. Concerns regarding in vitro and in vivo uses of thalidomide. Lepr Rev, 2005; 76: 94-96.
24. Moreira AL, Kaplan G, Villahermosa LG et al. Comparison of pentoxifylline, thalidomide and prednisolone in the treatment of ENL. Int J Lepr, 1998; 66: 61-65.
25. Shannon EJ. Thalidomide: will the past overshadow a promising future? The Star, 2000; 59: 10-13.
26. Naafs B. Treatment of leprosy: science or politics? Trop Med Int Health, 2006; 11: 268-278.
27. Lockwood DNJ, Bryceson A. The return of thalidomide: new uses and renewed concerns. Lepr Rev, 2003; 74: 290-294.
28. Naafs B. The return of thalidomide: new uses and renewed concerns. Lepr Rev, 2003; 74: 294-295.
29. Pereira GF. On thalidomide and WHO policies. Lepr Rev, 2003; 74: 288-290.
30. van Brakel WH, Nicholls PG, Lockwood DNJ et al. A scale to assess the severity of leprosy reactions. Lepr Rev, 2007; 78: 161-164.
31. Brandsma JW. Monitoring motor nerve function in leprosy patients. Lepr Rev, 2000; 71: 258-267.
32. Birke JA, Brandsma JW, Schreuders TAR, Piefer A. Sensory testing with monofilaments in Hansen's disease and normal control subjects. Int J Lepr, 2000; 68: 291-298.
33. Brakel WH, Nicholls PG, Das L et al. The INFIR cohort study: assessment of sensory and motor neuropathy at baseline. Lepr Rev, 2005; 76: 277-295.
34. Britton WJ, Lockwood DNJ. Leprosy. Lancet, 2004; 363: 1209-1219.
35. Scollard DM, Smith T, Bhoopat L et al. Epidemiologic characteristics of leprosy reactions. Int J Lepr, 1994; 62: 559-567.
36. Schreuder PAM. The occurrence of reactions and impairments in leprosy; experience in the leprosy control program of three provinces in north-eastern Thailand, 1978-1995. I. Overview of the study. Int J Lepr, 1998; 66: 149-158.
37. Faber WR, Jensema AJ, Goldschmidt WFM. Treatment of erythema nodosum leprosum with infiximab. N Engl J Med, 2006; 355: 739.
38. Verma KK, Srivasta P, Minz A, Verma K. Role of azathioprine in preventing recurrent erythema nodosum leprosum. Lepr Rev, 2006; 77: 225-229.